Antibody Drug Conjugates Global Market Opportunities And Strategies To 2033
Including: 1) By Linker Type: Cleavable Linker; Non-Cleavable Linker2) By Product: Kadcyla; Enhertu; Adcetris; Polivy; Trodelvy; Padcev3) By Application: Hematopoietic Cancers; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor4) By End User: Hospital; Clinics; Specialty CentersCovering: F. Hoffmann-La Roche Ltd.; Daiichi Sankyo Company Limited; Seagen Inc.; Gilead Sciences Inc.; Genmab
Antibody Drug Conjugates Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global antibody drug conjugates market as it emerges from the COVID-19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Where is the largest and fastest-growing market for antibody drug conjugates? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The antibody drug conjugates market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market’s history and forecasts market growth by geography. It places the market within the context of the wider antibody drug conjugates market; and compares it with other markets.
The report covers the following chapters
- Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by linker type, by product, by application and by end-user.
- Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
- Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the antibody drug conjugates market.
- Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
- Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by linker type, by product, by application and by end-user in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
- Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
- Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
- Other Major And Innovative Companies Details on the company profiles of other major and innovative companies in the market.
- Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
- Competitive Dashboard- Briefs on competitive dashboard of major players.
- Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
- Conclusions And Recommendations- This section includes recommendations for antibody drug conjugates providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
- Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
1) By Linker Type: Cleavable Linker; Non-Cleavable Linker
2) By Product: Kadcyla; Enhertu; Adcetris; Polivy; Trodelvy; Padcev; Other Products
3) By Application: Hematopoietic Cancers; Breast Cancer; Ovarian Cancer; Lung Cancer; Brain Tumor; Other Applications
4) By End User: Hospital; Clinics; Specialty Centers; Other End Users
Companies Mentioned: F. Hoffmann-La Roche Ltd.; Daiichi Sankyo Company Limited; Seagen Inc.; Gilead Sciences Inc.; Genmab
Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time-series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; antibody drug conjugates indicators comparison.
Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- 1 Executive Summary
- 1.1 Antibody Drug Conjugates – Market Attractiveness And Macro economic Landscape
- 2 Table Of Contents
- 3 List Of Tables
- 4 List Of Figures
- 5 Report Structure
- 6 Market Characteristics
- 6.1 General Market Definition
- 6.2 Summary
- 6.3 Antibody Drug Conjugates Market Definition And Segmentations
- 6.4 Market Segmentation By Linked Type
- 6.4.1 Cleavable Linker
- 6.4.2 Non-cleavable Linker
- 6.5 Market Segmentation By Product
- 6.5.1 Adcetris
- 6.5.2 Kadcyla
- 6.5.3 Enhertu
- 6.5.4 Polivy
- 6.5.5 Trodelvy
- 6.5.6 Padcev
- 6.5.7 Other Products
- 6.6 Market Segmentation By Application
- 6.6.1 Hematopoietic Cancers
- 6.6.2 Breast Cancer
- 6.6.3 Lung Cancer
- 6.6.4 Brain Tumor
- 6.6.5 Ovarian Cancer
- 6.6.6 Other Applications
- 6.7 Market Segmentation By End User
- 6.7.1 Hospitals And Clinics
- 6.7.2 Specialty Centers
- 6.7.3 Other End-Users
- 7 Major Market Trends
- 7.1 Strategic Partnerships And Collaborations Among Market Players
- 7.2 Significant Investments In R&D By Market Players
- 7.3 Focus On New mAb Targets For ADCs Development
- 8 Antibody Drug Conjugates Market - Macro Economic Scenario
- 8.1 COVID-19 Impact On The Antibody Drug Conjugates Market
- 8.2 Impact Of The War In Ukraine On The Antibody Drug Conjugates Market
- 8.3 Impact Of High Inflation On The Antibody Drug Conjugates Market
- 9 Global Market Size and Growth
- 9.1 Market Size
- 9.2 Historic Market Growth, 2018 – 2023, Value ($ Million)
- 9.2.1 Market Drivers 2018 – 2023
- 9.2.2 Market Restraints 2018 – 2023
- 9.3 Forecast Market Growth, 2023 – 2028, 2033F Value ($ Million)
- 9.3.1 Market Drivers 2023 – 2028
- 9.3.2 Market Restraints 2023 – 2028
- 10 Global Antibody Drug Conjugates Market Segmentation
- 10.1 Global Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 10.2 Global Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 10.3 Global Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 10.4 Global Antibody Drug Conjugates Market, Segmentation By Product, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11 Antibody Drug Conjugates Market, Regional and Country Analysis
- 11.1 Global Antibody Drug Conjugates Market, By Region, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 11.2 Global Antibody Drug Conjugates Market, By Country, Historic and Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12 Asia-Pacific Market
- 12.1 Summary
- 12.2 Market Overview
- 12.2.1 Region Information
- 12.2.2 Market Information
- 12.2.3 Background Information
- 12.2.4 Government Initiatives
- 12.2.5 Regulations
- 12.2.6 Regulatory Bodies
- 12.2.7 Major Associations
- 12.2.8 Taxes Levied
- 12.2.9 Corporate Tax Structure
- 12.2.10 Investments
- 12.2.11 Major Companies
- 12.3 Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.4 Asia-Pacific Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.5 Asia-Pacific Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.6 Asia-Pacific Antibody Drug Conjugates Market: Country Analysis
- 12.7 China Market
- 12.8 Summary
- 12.9 Market Overview
- 12.9.1 Country Information
- 12.9.2 Market Information
- 12.9.3 Background Information
- 12.9.4 Government Initiatives
- 12.9.5 Regulations
- 12.9.6 Regulatory Bodies
- 12.9.7 Major Associations
- 12.9.8 Taxes Levied
- 12.9.9 Corporate Tax Structure
- 12.9.10 Investments
- 12.9.11 Major Companies
- 12.10 China Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.11 China Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.12 China Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.13 India Market
- 12.14 India Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.15 India Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.16 India Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.17 Japan Market
- 12.18 Japan Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.19 Japan Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.20 Japan Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.21 Australia Market
- 12.22 Australia Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.23 Australia Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.24 Australia Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.25 Indonesia Market
- 12.26 Indonesia Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.27 Indonesia Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.28 Indonesia Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.29 South Korea Market
- 12.30 South Korea Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.31 South Korea Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 12.32 South Korea Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13 Western Europe Market
- 13.1 Summary
- 13.2 Market Overview
- 13.2.1 Region Information
- 13.2.2 Market Information
- 13.2.3 Background Information
- 13.2.4 Government Initiatives
- 13.2.5 Regulations
- 13.2.6 Regulatory Bodies
- 13.2.7 Major Associations
- 13.2.8 Taxes Levied
- 13.2.9 Corporate Tax Structure
- 13.2.10 Investments
- 13.2.11 Major Companies
- 13.3 Western Europe Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.4 Western Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.5 Western Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.6 Western Europe Antibody Drug Conjugates Market: Country Analysis
- 13.7 UK Market
- 13.8 UK Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.9 UK Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.10 UK Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.11 Germany Market
- 13.12 Germany Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.13 Germany Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.14 Germany Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.15 France Market
- 13.16 France Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.17 France Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.18 France Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.19 Italy Market
- 13.20 Italy Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.21 Italy Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.22 Italy Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.23 Spain Market
- 13.24 Spain Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.25 Spain Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 13.26 Spain Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14 Eastern Europe Market
- 14.1 Summary
- 14.2 Market Overview
- 14.2.1 Region Information
- 14.2.2 Market Information
- 14.2.3 Background Information
- 14.2.4 Government Initiatives
- 14.2.5 Regulations
- 14.2.6 Regulatory Bodies
- 14.2.7 Major Associations
- 14.2.8 Taxes Levied
- 14.2.9 Corporate Tax Structure
- 14.2.10 Investments
- 14.2.11 Major Companies
- 14.3 Eastern Europe Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.4 Eastern Europe Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.5 Eastern Europe Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.6 Eastern Europe Antibody Drug Conjugates Market: Country Analysis
- 14.7 Russia Market
- 14.8 Russia Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.9 Russia Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 14.10 Russia Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15 North America Market
- 15.1 Summary
- 15.2 Market Overview
- 15.2.1 Region Information
- 15.2.2 Market Information
- 15.2.3 Background Information
- 15.2.4 Government Initiatives
- 15.2.5 Regulations
- 15.2.6 Regulatory Bodies
- 15.2.7 Major Associations
- 15.2.8 Taxes Levied
- 15.2.9 Corporate Tax Structure
- 15.2.10 Investments
- 15.2.11 Major Companies
- 15.3 North America Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.4 North America Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.5 North America Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.6 North America Antibody Drug Conjugates Market: Country Analysis
- 15.7 USA Market
- 15.8 Summary
- 15.9 Market Overview
- 15.9.10 Country Information
- 15.9.2 Market Information
- 15.9.3 Background Information
- 15.9.4 Government Initiatives
- 15.9.5 Regulations
- 15.9.6 Regulatory Bodies
- 15.9.7 Major Associations
- 15.9.8 Taxes Levied
- 15.9.9 Corporate Tax Structure
- 15.9.10 Investments
- 15.9.11 Major Companies
- 15.10 USA Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.11 USA Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.12 USA Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.13 Canada Market
- 15.14 Canada Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.15 Canada Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 15.16 Canada Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16 South America Market
- 16.1 Summary
- 16.2 Market Overview
- 16.2.1 Region Information
- 16.2.2 Market Information
- 16.2.3 Background Information
- 16.2.4 Government Initiatives
- 16.2.5 Regulations
- 16.2.6 Regulatory Bodies
- 16.2.7 Major Associations
- 16.2.8 Taxes Levied
- 16.2.9 Corporate Tax Structure
- 16.2.10 Major Companies
- 16.3 South America Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.4 South America Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.5 South America Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.6 South America Antibody Drug Conjugates Market: Country Analysis
- 16.7 Brazil Market
- 16.8 Brazil Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.9 Brazil Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 16.10 Brazil Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17 Middle East Market
- 17.1 Summary
- 17.2 Market Overview
- 17.2.1 Region Information
- 17.2.2 Market Information
- 17.2.3 Background Information
- 17.2.4 Government Initiatives
- 17.2.5 Regulations
- 17.2.6 Regulatory Bodies
- 17.2.7 Major Associations
- 17.2.8 Taxes Levied
- 17.2.9 Corporate Tax Structure
- 17.2.10 Major Companies
- 17.3 Middle East Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17.4 Middle East Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 17.5 Middle East Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 18 Africa Market
- 18.1 Summary
- 18.2 Market Overview
- 18.2.1 Region Information
- 18.2.2 Market Information
- 18.2.3 Background Information
- 18.2.4 Government Initiatives
- 18.2.5 Regulations
- 18.2.6 Regulatory Bodies
- 18.2.7 Major Associations
- 18.2.8 Taxes Levied
- 18.2.9 Corporate Tax Structure
- 18.2.10 Major Companies
- 18.3 Africa Antibody Drug Conjugates Market, Segmentation By Linker Type, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 18.4 Africa Antibody Drug Conjugates Market, Segmentation By Application, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 18.5 Africa Antibody Drug Conjugates Market, Segmentation By End User, Historic And Forecast, 2018 – 2023, 2028F, 2033F, Value ($ Million)
- 19 Competitive Landscape and Company Profiles
- 19.1 Company Profiles
- 19.1 F. Hoffman-La Roche Ltd
- 19.1.1 Company Overview
- 19.1.2 Products And Services
- 19.1.3 Business Strategy
- 19.1.4 Financial Overview
- 19.2 Daiichi Sankyo Company Limited
- 19.2.1 Company Overview
- 19.2.2 Products And Services
- 19.2.3 Business Strategy
- 19.2.4 Financial Overview
- 19.3 Seagen Inc
- 19.3.1 Company Overview
- 19.3.2 Products And Services
- 19.3.3 Business Strategy
- 19.3.4 Financial Overview
- 19.4 Gilead Sciences Inc
- 19.4.1 Company Overview
- 19.4.2 Products And Services
- 19.4.3 Business Strategy
- 19.4.4 Financial Overview
- 19.5 Genmab A/S
- 19.5.1 Company Overview
- 19.5.2 Products And Services
- 19.5.3 Business Strategy
- 19.5.4 Financial Overview
- 20 Other Major And Innovative Companies
- 20.1 Pfizer
- 20.1.1 Company Overview
- 20.1.2 Products And Services
- 20.2 GlaxoSmithKline plc
- 20.2.1 Company Overview
- 20.2.2 Products And Services
- 20.3 ADC Therapeutics SA
- 20.3.1 Company Overview
- 20.3.2 Products And Services
- 20.4 AstraZeneca plc
- 20.4.1 Company Overview
- 20.4.2 Products And Services
- 20.5 RemeGen
- 20.5.1 Company Overview
- 20.5.2 Products And Services
- 20.6 Astellas Pharma Inc.
- 20.6.1 Company Overview
- 20.6.2 Products And Services
- 20.7 ImmunoGen Inc.
- 20.7.1 Company Overview
- 20.7.2 Products And Services
- 20.8 Rakuten Medical
- 20.8.1 Company Overview
- 20.8.2 Products And Services
- 20.9 Takeda Pharmaceutical Company Limited
- 20.9.1 Company Overview
- 20.9.2 Products And Services
- 20.10 AbbVie Inc.
- 20.10.1 Company Overview
- 20.10.2 Products And Services
- 20.11 Mersana Therapeutics Inc.
- 20.11.1 Company Overview
- 20.11.2 Products And Services
- 20.12 Merck Co. & KGaA
- 20.12.1 Company Overview
- 20.12.2 Products And Services
- 20.13 Bristol Myers Squibb Co.
- 20.13.1 Company Overview
- 20.13.2 Products And Services
- 20.14 Novo Nordisk A/S
- 20.14.1 Company Overview
- 20.14.2 Products And Services
- 20.15 Bayer AG
- 20.15.1 Company Overview
- 20.15.2 Products And Services
- 21 Competitive Benchmarking
- 22 Competitive Dashboard
- 23 Key Mergers And Acquisitions
- 23.1 Genmab A/S Acquired ProfoundBio Inc
- 23.2 Johnson & Johnson (J&J) Acquired Ambrx Biopharma Inc
- 23.3 AbbVie Acquired ImmunoGen, Inc
- 23.4 Pfizer Inc Acquired Seagen Inc
- 24 Opportunities And Strategies
- 24.1 Global Antibody Drug Conjugates Market In 2028 – Countries Offering Most New Opportunities
- 24.2 Global Antibody Drug Conjugates Market In 2028 – Segments Offering Most New Opportunities
- 24.3 Global Antibody Drug Conjugates Market In 2028 – Growth Strategies
- 24.3.1 Market Trend Based Strategies
- 24.3.2 Competitor Strategies
- 25 Antibody Drug Conjugates Market, Conclusions And Recommendations
- 25.1 Conclusions
- 25.2 Recommendations
- 25.2.1 Product
- 25.2.2 Place
- 25.2.3 Price
- 25.2.4 Promotion
- 25.2.5 People
- 26 Appendix
- 26.1 Geographies Covered
- 26.2 Market Data Sources
- 26.3 Research Methodology
- 26.4 Currencies
- 26.5 The Business Research Company
- 26.6 Copyright and Disclaimer
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook